Does Bimzelx Work After Humira Failure?
Bimzelx (bimekizumab) shows efficacy in patients who failed Humira (adalimumab), particularly for moderate-to-severe plaque psoriasis. In the BE VIVID and BE READY phase 3 trials, about 40-50% of participants had prior biologic exposure, including anti-TNFs like Humira. Among those, Bimzelx achieved PASI 90 (90% skin clearance) in 52-58% of patients at week 16, compared to 9-15% on placebo.[1][2] Real-world data from registries like those in Europe report similar response rates, with 60-70% of Humira-failures reaching PASI 90 by week 16.[3]
How Does Bimzelx Differ from Humira Mechanistically?
Humira blocks TNF-alpha, while Bimzelx dual-inhibits IL-17A and IL-17F, cytokines central to psoriasis inflammation. This targets a downstream pathway, explaining why it works post-TNF failure—IL-17 drives disease even when TNF is suppressed.[4] Head-to-head data isn't available, but in trials with Humira-experienced patients, Bimzelx outperformed ustekinumab (an IL-12/23 inhibitor) on speed and depth of response.[1]
What About Other Conditions Like Psoriatic Arthritis or Hidradenitis Suppurativa?
For psoriatic arthritis (PsA), BE OPTIMAL and BE COMPLETE trials included 30-40% with prior anti-TNF failure; Bimzelx hit ACR50 (50% joint improvement) in 45-52% at week 16 versus 24% on placebo.[5] In hidradenitis suppurativa (HS), phase 3 BE HEARD trials enrolled 40% anti-TNF failures, with HiSCR50 (50% lesion reduction) in 45-52% on Bimzelx versus 30% placebo.[6] Efficacy holds across these, though response may dip slightly in multi-biologic failures.
Common Side Effects in Switchers from Humira
Patients switching report similar tolerability: oral candidiasis (10-15%), upper respiratory infections (15-20%), and injection-site reactions (5-10%). Rates don't rise significantly post-Humira.[2][5] No new safety signals in biologic-experienced groups.
Who Makes Bimzelx and When Do Patents Expire?
UCB manufactures Bimzelx, approved by FDA in 2023 for psoriasis, 2024 for PsA and HS. Key U.S. patents expire around 2035-2038, per DrugPatentWatch.com.[7] No major challenges yet, delaying biosimilars.
Sources
[1]: NEJM - BE VIVID/BE READY
[2]: JAAD - Bimzelx Pivotal Trials
[3]: British Journal of Dermatology - Real-World Bimzelx
[4]: Nature Reviews Drug Discovery - IL-17 Pathway
[5]: Lancet - BE OPTIMAL/COMPLETE
[6]: FDA Label - BE HEARD
[7]: DrugPatentWatch.com - Bimzelx Patents